Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 0.68 |
| ▸ | MEN1 | O00255 | 6/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.56 |
| ▸ | FGB | P02675 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.56 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7786089 | 0.93 | RAB9A (0.87) | RAB9ASMN1; SMN2NPC1MAPTMEN1 | |
| SCHEMBL12253692 | 0.87 | RAB9A (0.76) | RAB9ASMN1; SMN2NPC1MAPTMEN1 | |
| SCHEMBL4700188 | 0.84 | RAB9A (0.71) | RAB9ASMN1; SMN2NPC1MAPTMEN1 | |
| SCHEMBL5146135 | 0.82 | SMN1; SMN2 (0.69) | RAB9ASMN1; SMN2NPC1MAPTMEN1 | |
| SCHEMBL1426442 | 0.82 | SMN1; SMN2 (0.70) | RAB9ASMN1; SMN2NPC1MAPTMEN1 | |
| SCHEMBL3419749 | 0.82 | SMN1; SMN2 (0.70) | RAB9ASMN1; SMN2NPC1MAPTMEN1 | |
| SCHEMBL29906115 | 0.82 | SMN1; SMN2 (0.70) | RAB9ASMN1; SMN2NPC1MAPTMEN1 | |
| SCHEMBL4706459 | 0.81 | RAB9A (0.67) | RAB9ASMN1; SMN2NPC1MAPTMEN1 | |
| SCHEMBL9846590 | 0.81 | RAB9A (0.68) | RAB9ASMN1; SMN2NPC1MAPTMEN1 | |
| SCHEMBL9751849 | 0.81 | RAB9A (0.68) | RAB9ASMN1; SMN2NPC1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3943085-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2022-01-26 | — | — | EP | claimed |
| US-20210186947-A1 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH ZURICH (CH) | 2021-06-24 | — | — | US | claimed |
| CN-108957895-B | Acid-base responsive electrochromic film, preparation method and application thereof, and electrochromic device | 常州铱视光电科技有限公司 | 2021-06-11 | — | — | CN | claimed |
| CN-108873537-B | Electrochromic film, preparation method and application thereof, and electrochromic device | 常州铱视光电科技有限公司 | 2021-06-04 | — | — | CN | claimed |
| EP-3801507-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2021-04-14 | — | — | EP | claimed |
| US-4278607-A | Process for the preparation of dimethoxyanthraquinones | BAYER AKTIENGESELLSCHAFT (DE) | 1981-07-14 | — | — | US | claimed |
| CN-110520433-B | Phosphorus-containing phenol compound, phosphorus-containing epoxy resin, curable resin composition or epoxy resin composition, and cured product thereof | 日铁化学材料株式会社 | 2023-12-05 | — | — | CN | disclosed |
| US-20230320940-A1 | PHOTOCATIONICALLY CURABLE COMPOSITION AND DENTAL CURABLE COMPOSITION | TOKUYAMA DENTAL CORPORATION (JP) | 2023-10-12 | — | — | US | disclosed |
| CN-110951048-B | Phosphorus-containing hardener, epoxy resin composition, cured product, prepreg, and laminate | 日铁化学材料株式会社 | 2023-09-29 | — | — | CN | disclosed |
| EP-4194477-A1 | PHOTOCATIONIC CURABLE COMPOSITION AND CURABLE DENTAL COMPOSITION | Tokuyama Dental Corporation (JP) | 2023-06-14 | — | — | EP | disclosed |
| CN-110194843-B | Phosphorus-containing phenoxy resin, resin composition, material for circuit board, and cured product | 日铁化学材料株式会社 | 2023-01-03 | — | — | CN | disclosed |
| EP-3943085-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2022-01-26 | — | — | EP | disclosed |
| CN-113750197-A | Traditional Chinese medicine composition for controlling blood sugar, capsule and preparation method of capsule | 珠海中科先进技术研究院有限公司 | 2021-12-07 | — | — | CN | disclosed |
| US-4278607-A | Process for the preparation of dimethoxyanthraquinones | BAYER AKTIENGESELLSCHAFT (DE) | 1981-07-14 | — | — | US | disclosed |
| US-4278607-A | Process for the preparation of dimethoxyanthraquinones | BAYER AKTIENGESELLSCHAFT (DE) | 1981-07-14 | — | — | US | disclosed |
| EP-0014367-A1 | Process for the preparation of dimethoxyanthraquinones | BAYER AG (DE) | 1980-08-20 | — | — | EP | disclosed |
| EP-0014367-A1 | Process for the preparation of dimethoxyanthraquinones | BAYER AG (DE) | 1980-08-20 | — | — | EP | disclosed |
| EP-0014367-A1 | Process for the preparation of dimethoxyanthraquinones | BAYER AG (DE) | 1980-08-20 | — | — | EP | disclosed |
| US-4080370-A | Process for producing high purity methoxyanthraquinones | MITSUBISHI CHEMICAL INDUSTRIES, LTD. (JA) | 1978-03-21 | — | — | US | disclosed |
| US-3983145-A | Use of alpha-di(lower alkoxy) anthraquinones in the synthesis of Alizarin Saphirols | TOMS RIVER CHEMICAL CORPORATION (US) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230320940-A1 | PHOTOCATIONICALLY CURABLE COMPOSITION AND DENTAL CURABLE COMPOSITION | CTH, GCLC, AAAS | RAB9A 2337/4885SMN1; SMN2 3290/4885NPC1 4742/4885 |
| US-20210186947-A1 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | TOMM70, TOMM34, TIMM50 | RAB9A 3373/4885SMN1; SMN2 4118/4885NPC1 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.